Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl‐1 degradation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl‐1 degradation

Published:2019-05-02 Issue:8 Volume:58 Page:1502-1511
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Mol Carcinog

Author:

Liang Huaxin¹,Chen Zhuo¹,Sun Libo¹

Affiliation:

1. Department of NeurosurgeryChina‐Japan Union Hospital of Jilin UniversityChangchun Jilin China

Funder

Natural Science Foundation of Jilin Provincial Science and Technology Department

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23034

Reference35 articles.

1. Adult glioma incidence trends in the United States, 1977-2000

2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

3. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma

4. Cell cycle‐mediated drug resistance: an emerging concept in cancer therapy;Shah MA;Clin Cancer Res,2001

5. Apoptosis in cancer therapy: Crossing the threshold

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of new targets for glioblastoma therapy based on a DNA expression microarray;Computers in Biology and Medicine;2024-09

2. Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT;Scientific Reports;2024-08-30

3. Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells;Scientific Reports;2023-12-09

4. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers;British Journal of Cancer;2023-08-24

5. Targeting CDK7 in oncology: The avenue forward;Pharmacology & Therapeutics;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3